Abstracts tagged "mycophenolate mofetil"

Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Rajaie Namas^1,2, Donald P. Tashkin³, Holly Wilhalme⁴, Daniel E. Furst⁵, Chi-hong Tseng⁶, Michael Roth⁶, Suzanne Kafaja⁷, Elizabeth R. Volkmann⁴, Philip J. Clements⁶ and Dinesh Khanna⁸, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Michigan, Ann Arbor, MI
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…
Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Dinesh Khanna², Chi-hong Tseng³, Robert Elashoff⁴, Bingling Wang⁵, Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Arthur Theodore⁶ and Donald P. Tashkin⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁵Biostatistics, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine, Boston University, Boston, MA, ⁷David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
Abstract Number: 2921 • 2015 ACR/ARHP Annual Meeting
Lupus Nephritis: An Exploration of Management Style
Abhishek Nandan¹, Huzaefah Syed², Christen Vagts¹ and Jason Kidd¹, ¹Virginia Commonwealth University Medical Center, Richmond, VA, ²Rheumatology, Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: We aim to evaluate the differences and rationale behind the diagnostic and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and rheumatologists. Methods:…
Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Lesley Ann Saketkoo¹, Dörte Huscher², Christopher P. Denton³, Gabriela Riemekasten⁴, Virginia D. Steen⁵, Oliver Distler⁶ and EUSTAR member centres, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, ⁵Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…
Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Philip J. Clements¹, Donald Tashkin¹, Michael Roth¹, Dinesh Khanna², Daniel E. Furst³, Chi-hong Tseng¹, Elizabeth R. Volkmann¹ and Robert Elashoff⁴, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA
Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
Abstract Number: 2427 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Alice Brambilla¹, Alessandra Cosi², Anna Rosati², Renzo Guerrini², Rolando Cimaz¹ and Gabriele Simonini¹, ¹Pediatric Rheumatology, Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Neurology Unit, Neurology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy
Background/Purpose: Childhood primary central nervous system vasculitis (cPANCS) is an inflammatory brain disease targeting either small (angiography-negative) or medium-large (angiography-positive) central nervous system vessels. Vascular…
Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1685 • 2014 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Michael Pham¹ and W Leroy Griffing², ¹Division of Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Division of Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Interstitial lung disease remains a primary driver of morbidity and mortality in patients suffering from systemic sclerosis. Cyclophosphamide currently is the treatment with the…
Abstract Number: 1684 • 2014 ACR/ARHP Annual Meeting
Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study
Audrey Bearden¹, Kent Kwasind Huston² and Judy Foxworth³, ¹Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, ²Rheumatology, The Center for Rheumatic Disease, Kansas City, MO, ³Associate Program Director & Director of Research, The University of Missouri-Kansas City, Kansas City, MO
Background/Purpose: Interstitial lung disease occurs in over 80% of patients with scleroderma. Cyclophosphamide is the only treatment proven to benefit scleroderma lung disease in a…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Jessica K. Gordon³, Paula Lauto⁴ and Virginia D. Steen⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
Abstract Number: 837 • 2012 ACR/ARHP Annual Meeting
Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase
Noa Schwartz¹, Tejaskumar Patel¹, Ellen M. Ginzler², Neil Solomons³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ³Vifor Pharma, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: The Aspreva Lupus Management Study (ALMS) demonstrated the efficacy of mycophenolate mofetil (MMF-a prodrug of MFA, mycophenolic acid) for both induction and maintenance of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].